

Molecular Haemato-Oncology Trial Schedule 2024 – 2025

| Accredited Programmes  | Trial issue | APR 24 | MAY 24 | JUN 24 | JUL 24 | AUG 24 | SEP 24 | OCT 24 | NOV 24 | DEC 24 | JAN 25 | FEB 25 | MAR 25 |
|--|-------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| <b>BCR::ABL1 and AML Translocation Identification</b>                    | 3           | X      |        |        |        | X      |        |        |        | X      |        |        |        |
| <b>BCR::ABL1 Kinase Domain Variant (Mutation) Status</b>                 | 3           |        |        | X      |        |        |        | X      |        |        |        | X      |        |
| <b>BCR::ABL1 Major Quantification</b>                                    | 3           |        | X      |        |        |        | X      |        |        |        | X      |        |        |
| <b>BCR::ABL1 Minor Quantification</b>                                    | 3           |        | X      |        |        |        | X      |        |        |        | X      |        |        |
| <b>BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia</b> | 3           | X      |        |        | X      |        |        |        |        | X      |        |        |        |
| <b>FLT3 Mutation Status</b>  | 3           |        |        |        | X      |        |        |        | X      |        |        |        | X      |
| <b>IG/TCR Clonality Status</b>   | 3           | X      |        |        |        | X      |        |        |        | X      |        |        |        |
| <b>KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease</b>     | 3           |        | X      |        |        |        | X      |        |        |        | X      |        |        |
| <b>Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia</b>         | 2           |        |        | X      |        |        |        |        | X      |        |        |        |        |
| <b>Myeloproliferative Neoplasms Diagnostic Testing <sup>1</sup></b>      | 4           |        |        | X      |        |        | X      |        |        | X      |        |        | X      |
| <b>NPM1 Mutation Status</b>  | 3           |        |        |        | X      |        |        |        | X      |        |        |        | X      |
| <b>Paediatric Acute Leukaemia Translocations</b>                         | 3           |        |        | X      |        |        |        | X      |        |        |        | X      |        |
| <b>Post-Stem Cell Transplant Chimerism Monitoring</b>                    | 5           |        | X      |        | X      |        |        | X      |        | X      |        | X      |        |

| Non-accredited Programmes   | Trial Issue | APR 24 | MAY 24 | JUN 24 | JUL 24 | AUG 24         | SEP 24         | OCT 24 | NOV 24 | DEC 24 | JAN 25 | FEB 25         | MAR 25         |
|---|-------------|--------|--------|--------|--------|----------------|----------------|--------|--------|--------|--------|----------------|----------------|
| <b>Lymphoid Gene Panels</b>   | 2           |        |        |        |        |                | X <sup>2</sup> |        |        |        |        |                | X <sup>3</sup> |
| <b>Measurable Residual Disease for Acute Myeloid Leukaemia by Molecular Methods</b> | 2           |        |        |        |        | X              |                |        |        |        |        |                | X              |
| <b>Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods</b>      | 2           |        |        | X      |        |                |                |        | X      |        |        |                |                |
| <b>Myeloid Gene Panels</b>  | 2           |        |        |        |        | X <sup>2</sup> |                |        |        |        |        | X <sup>3</sup> |                |

1. The JAK2 p.V617F mutation status and MPN DT programmes have now been merged and include testing of JAK2 p.V617F, JAK2 exon 12, CALR and MPL. Please note, only the JAK2 p.V617F aspect of testing is currently accredited. We are working towards accreditation for the other markers. 2. Includes educational focus. 3. Technical

Authorised on: 12-Jun-2024. Authorised by: Stuart Scott. Document Unique Reference: view only. Due for review on: 12-Jun-2025. Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.